Conclusion
SCLC, toxicities
SCLC
Antiangiogenic therapy plus chemotherapy had encouraging efficacy in advanced SCLC patients, which provides an insight into the current status of second‐line therapy in SCLC.Antiangiogenic therapy (Apatinib) plus chemotherapy had better efficacy compared with standard second‐line chemotherapies for advanced SCLC patients. No more intolerable toxicities were observed for this new regimen, which should provide a highlight view on the current status of second‐line therapy in SCLC.
Yinghui Xu, Xu Wang, Chao Sun, and Zhiru Gao contributed equally.